Adrienne Kirby

Susanna B. Park1
Cindy S.-Y. Lin1
1Susanna B. Park
1Cindy S.-Y. Lin
Learn More
SAMPLE SIZE MUST BE PLANNED carefully to ensure that the research time, patient effort and support costs invested in any clinical trial are not wasted. Item 7 of the CONSORT statement relates to the sample size and stopping rules of studies (see Box 1); it states that the choice of sample size needs to be justified. 1 Ideally, clinical trials should be(More)
  • Anna P. Ralph, Clancy Read, Vanessa Johnston, Jessica L. de Dassel, Kerstin Bycroft, Alice Mitchell +6 others
  • 2016
BACKGROUND Rheumatic heart disease (RHD), caused by acute rheumatic fever (ARF), is a major health problem in Australian Aboriginal communities. Progress in controlling RHD requires improvements in the delivery of secondary prophylaxis, which comprises regular, long-term injections of penicillin for people with ARF/RHD. METHODS/DESIGN This trial aims to(More)
BACKGROUND Abnormalities in membrane excitability and Na(+) channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na(+) channel blocker and membrane stabiliser flecainide in ALS. METHODS A double-blind, placebo-controlled, randomised clinical trial of(More)
BACKGROUND Traditional methods for analyzing clinical and epidemiological cohort study data have been focused on the first occurrence of a health outcome. However, in many situations, recurrent event data are frequently observed. It is inefficient to use methods for the analysis of first events to analyse recurrent event data. METHODS We applied several(More)
  • 1